HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Quashes Claims That Ibuprofen Worsens Infection From Coronavirus

Executive Summary

Breaking News: The European Medicines Agency says there is no evidence that ibuprofen worsens Covid‑19 and that consumers can carry on using the drug as advised by patient information. 

You may also be interested in...



AESGP Annual Meeting, Day 2: Communicating Risk, E-Commerce Boom, RWE And Sustainability

Day two of the AESGP's 57th Annual Meeting featured discussions on communicating risk in times of uncertainty, how to foster a harmonized EU market for food supplements and the growth of the ePharmacy channel. The opportunities presented by real-world evidence were also debated, along with the challenges facing the self-care industry in the area of sustainability.

Tylenol Leads OTC Acetaminophen Sales Surge After Ibuprofen Scare During Pandemic – IRI

J&J leads sales growth in OTC pain relief and allergy categories in 2020 as its brands benefited from competing products’ problems and COVID-19’s impact of consumer habits. IRI reveals winning brands that kept a focus on maintaining health in 2020.

Next Generation OTC Painkillers And Cough Syrup On Cards For German Switch Committee

Rx-to-OTC switches of the painkillers dexibuprofen and single-pill combinations of ibuprofen and paracetamol as well as the cough medicine levodropropizine, all for oral use, will be considered at the next German Expert Committee for Prescription meeting on 13 July.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel